Journal: Journal of Cancer Research and Clinical Oncology

Article Title: Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma

doi: 10.1007/s00432-026-06442-8

Figure Lengend Snippet: SLC6A8 is upregulated in HCC and correlated with poor prognosis of HCC patients. A Expression box plot of SLC6A8 in HCC patients from the GEPIA online database. B The correlation between SLC6A8 expression and 5-year overall survival analyzed by Kaplan-Meier plotter. C The fold change of SLC6A8 mRNA levels in HCC tumor tissues compared to matched para-cancerous tissues using qRT-PCR. C: cancer tissues; N: adjacent normal tissues. And Percentage of SLC6A8 expression alteration in 30 paired of HCC samples. Upregulated: C/ N > 1.5; Downregulated: C/ N < 0.67. D Representative IHC staining images displayed different levels of SLC6A8. Scale bars, up: 200 μm; down: 50 μm. E The AOD values of SLC6A8 protein in tumor and normal tissues from TMA. F Quantification of SLC6A8 expression in tumor and normal tissues from TMA. G The overall survival curve analyzed by Kaplan-Meier for HCC patients with a high or low level of SLC6A8 protein level. * P < 0.05, ** P < 0.01

Article Snippet: Immunohistochemistry (IHC) was carried out with an anti-SLC6A8 antibody (dilution 1:50; 20299-1-AP; Proteintech, China) following the manufacturer’s instructions.

Techniques: Expressing, Quantitative RT-PCR, Immunohistochemistry

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma

doi: 10.1007/s00432-026-06442-8

Figure Lengend Snippet: SLC6A8 knockdown suppresses HCC cell growth in vitro. A The efficiency of siSLC6A8 transfection in HCC cells assessed by Western blotting. B CCK-8 assays for HCC cells transfected with siSLC6A8-1, siSLC6A8-2 or siNC. C Colony formation assays for HCC cells transfected with siSLC6A8-1, siSLC6A8-2 or siNC. D Transwell migration assays for HCC cells transfected with siSLC6A8-1, siSLC6A8-2 or siNC. Scale bars, 100 μm. * P < 0.05, ** P < 0.01

Article Snippet: Immunohistochemistry (IHC) was carried out with an anti-SLC6A8 antibody (dilution 1:50; 20299-1-AP; Proteintech, China) following the manufacturer’s instructions.

Techniques: Knockdown, In Vitro, Transfection, Western Blot, CCK-8 Assay, Migration

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma

doi: 10.1007/s00432-026-06442-8

Figure Lengend Snippet: SLC6A8 inhibitor RGX-202 exhibits potent antitumor effects in HCC cells. A Cell viability for HCC cells treated with 0, 10 and 20mM RGX-202 assessed by CCK-8 assays B Effect on cell proliferation of RGX202 in HCC cells assessed by Colony formation assays exposed to 0, 5 and 10mM RGX-202. * P < 0.05, ** P < 0.01

Article Snippet: Immunohistochemistry (IHC) was carried out with an anti-SLC6A8 antibody (dilution 1:50; 20299-1-AP; Proteintech, China) following the manufacturer’s instructions.

Techniques: CCK-8 Assay

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma

doi: 10.1007/s00432-026-06442-8

Figure Lengend Snippet: Targeting SLC6A8 suppresses tumorigenicity of HCC cells in nude mice model. A HCC-LM3 cells with stable SLC6A8 knockdown used for Subcutaneous xenograft model of nude mice ( n = 5 per group). Representative images of tumors (left), tumor weight (middle), and tumor volume (right). B xenografts from HCC-LM3 cells with or without the treatment of RGX-202 (500 mg/kg, orally gavage once a day, n = 5 per group). Representative images of tumors (left), tumor weight (middle), and tumor volume (right). * P < 0.05, ** P < 0.01

Article Snippet: Immunohistochemistry (IHC) was carried out with an anti-SLC6A8 antibody (dilution 1:50; 20299-1-AP; Proteintech, China) following the manufacturer’s instructions.

Techniques: Knockdown

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: Targeting SLC6A8 suppresses tumor growth and enhances ferroptosis in hepatocellular carcinoma

doi: 10.1007/s00432-026-06442-8

Figure Lengend Snippet: SLC6A8 inhibition sensitizes HCC cells to ferroptosis. A Cell growth curve of Huh7 and HCC-LM3 shSLC6A8 and shNC treated with vehicle control, and 0.25μM RSL3 or 0.25μM RSL3 plus 1μM Fer-1 using CCK-8 assays. B Intracellular MDA levels of Huh7 shSLC6A8 and shNC treated with vehicle control, 1μM RSL3, and 1μM RSL3 plus 1μM Fer-1 for 24h. C – D Intracellular ROS content of Huh7 shSLC6A8 and shNC treated with control, 1μM RSL3, and 1μM RSL3 plus 1μM Fer-1 observed using fluorescence microscope and quantified using flow cytometry. Scale bar: 100µm. E xenografts from HCC-LM3 cells with treatment of control, RGX-202 (500mg/kg, orally gavage once a day), RSL3 (10mg/kg, administrated intraperitoneally every other day), or combination of RGX-202 and RSL3. Representative images of tumors (left), tumor weight (middle), and tumor volume (right). * P < 0.05, ** P < 0.01

Article Snippet: Immunohistochemistry (IHC) was carried out with an anti-SLC6A8 antibody (dilution 1:50; 20299-1-AP; Proteintech, China) following the manufacturer’s instructions.

Techniques: Inhibition, Control, CCK-8 Assay, Fluorescence, Microscopy, Flow Cytometry

Journal: Nature communications

Article Title: Multiple structures of RNA polymerase II isolated from human nuclei by ChIP-CryoEM analysis.

doi: 10.1038/s41467-025-59580-x

Figure Lengend Snippet: Fig. 2 | Details of the EC-SPT4/5-ELOF1-SPT6 structure. a Domain architectures of the elongation factors. The known domains are indicated. b Close-up view of ELOF1 (purple). c Close-up view around the upstream DNA. d Close-up view of the SPT5 KOW2, KOW3, KOWx, and KOW4 domains. Each KOW domain is indicated with dotted circles. SPT6 is omitted for clarity. e Close-up view of the KOW5 domain. f The SPT6-SPT5 KOW3-RPB4/7 stalk interaction. g The SPT5 KOW1-SPT6

Article Snippet: Themembraneswerewashedwith TBS-T (20mMTris-HCl (pH 7.5), 137mM NaCl, and 0.1% Tween-20) three times and then incubated overnight with anti-FLAG M2 antibody (Sigma # F3165, 1:3000), anti-SPT5 antibody (Proteintech#16511-1-AP, 1:1000), antiSPT6 antibody (Cell Signaling #15616, 1:2000), anti-PAF1 antibody (Cell Signaling #12883, 1:300), anti-RTF1 antibody (Proteintech #12170-1-AP, 1:1000), anti-MED17 antibody (Proteintech#11505-1-AP, 1:2000), or anti-XPB antibody (Cell Signaling #8746, 1:300) in Can Get Signal Immunoreaction Enhancer Solution 1 (TOYOBO #NKB-101).

Techniques:

Journal: Autophagy

Article Title: Regulation of N-degron recognin-mediated autophagy by the SARS-CoV-2 PLpro ubiquitin deconjugase

doi: 10.1080/15548627.2024.2442849

Figure Lengend Snippet: Reagents used in the investigation.

Article Snippet: pEGFP N1 Ub-CRT , Addgene , 69619; Marta Hallak lab.

Techniques: Recombinant, Diagnostic Assay, DC Protein Assay, Transfection, Mutagenesis, Plasmid Preparation, Gel Extraction, Purification, Cell Culture, shRNA